Research shows that a cellular stress response called ER stress damages blood vessels in diabetes by activating harmful signaling pathways. A Gram Research analysis of a 2026 study found that two compounds—4-phenylbutyric acid and the natural extract jatrorrhizine—improved blood vessel function in diabetic mice by reducing this stress and blocking these pathways. While promising, human trials are needed before these treatments become available.
According to Gram Research analysis, scientists discovered that a stress response inside cells called ER stress damages blood vessels in people with diabetes. They tested two compounds—one called 4-phenylbutyric acid and a natural plant extract called jatrorrhizine—on mice with high-fat diets and found both improved blood vessel function by reducing this harmful stress. The study involved 102 mice and human cell cultures, revealing that blocking specific signaling pathways could protect blood vessels from diabetes-related damage. This discovery opens new possibilities for treating diabetes complications that affect the heart and blood vessels.
Key Statistics
A 2026 research study of 102 mice found that 4-phenylbutyric acid and jatrorrhizine improved blood vessel relaxation in diabetic mice by reducing endoplasmic reticulum stress and blocking YAP/TAZ-SMAD1/5 signaling pathways.
In human blood vessel cells exposed to high glucose, ER stress alleviators significantly increased nitric oxide bioavailability and inhibited harmful YAP/TAZ-SMAD1/5 signaling, according to the 2026 Acta Pharmacologica Sinica study.
The 2026 research identified that YAP/TAZ and SMAD1/5 proteins bind together more strongly under high-glucose conditions, with this enhanced binding representing a key mechanism of diabetes-related blood vessel damage.
Jatrorrhizine, a natural plant compound, performed as effectively as the synthetic compound 4-phenylbutyric acid in protecting blood vessel function in the 102-mouse study, suggesting natural products may offer therapeutic potential.
The Quick Take
- What they studied: Whether reducing stress inside cells (called ER stress) could fix blood vessel problems caused by diabetes
- Who participated: 102 male mice fed a high-fat diet for 15 weeks to mimic diabetes, plus human blood vessel cells grown in lab dishes
- Key finding: Two compounds—4-phenylbutyric acid and jatrorrhizine—improved blood vessel function by reducing internal cell stress and blocking harmful signaling pathways
- What it means for you: These findings suggest new drug targets for diabetes complications, though human trials are needed before these treatments become available. People with diabetes should continue following their doctor’s current treatment plans.
The Research Details
Researchers created a diabetes-like condition in mice by feeding them a high-fat diet for 15 weeks. Then they gave some mice two test compounds for 5 weeks: 4-phenylbutyric acid (a stress-reducing chemical) and jatrorrhizine (a natural plant extract). They measured how well the mice’s blood vessels relaxed and compared treated mice to untreated ones.
The team also grew human blood vessel cells in dishes and exposed them to high sugar levels (mimicking diabetes) and various test compounds. They measured changes in stress markers, harmful molecules called free radicals, and specific signaling proteins inside the cells.
The researchers examined different sections of the mouse aorta (the main artery) separately because they suspected different regions might respond differently to the treatments.
This approach is important because it combines animal studies with human cell cultures, giving researchers confidence the findings might apply to people. By testing different blood vessel regions separately, they discovered that diabetes affects different parts of blood vessels in different ways—a detail previous research missed.
The study used a standard mouse model of diabetes (high-fat diet) that’s well-established in research. The researchers measured multiple markers of cell stress and blood vessel function, not just one outcome. However, this is early-stage research in animals and cells, not yet tested in humans. The study was published in a peer-reviewed journal, meaning other scientists reviewed it before publication.
What the Results Show
Both 4-phenylbutyric acid and jatrorrhizine improved how well blood vessels relaxed in diabetic mice—a key sign of healthy blood vessel function. These compounds worked by reducing ER stress (a type of cellular damage) and blocking harmful signaling pathways called YAP/TAZ-SMAD1/5.
In human blood vessel cells, the stress-reducing compounds increased nitric oxide, a molecule that helps blood vessels relax and function properly. Interestingly, simply blocking YAP/TAZ (one part of the harmful pathway) wasn’t enough—the compounds had to reduce the underlying ER stress first.
The researchers discovered that different parts of the aorta showed different patterns of signaling activation. The thoracic aorta (lower part) showed high YAP/TAZ activation, while the aortic arch (upper part) showed high SMAD1/5 activation. This regional difference suggests diabetes damages different blood vessel areas through different mechanisms.
The study found that YAP/TAZ and SMAD1/5 proteins physically bind together, and this binding increases dramatically when cells are exposed to high glucose (mimicking diabetes). This interaction appears to be a key step in how diabetes damages blood vessels. Additionally, jatrorrhizine, a natural compound from plants, worked as well as the synthetic 4-phenylbutyric acid, suggesting natural products might offer therapeutic options.
Previous research showed that YAP/TAZ and SMAD1/5 signaling contribute to atherosclerosis (plaque buildup in arteries), but their specific role in diabetes-related blood vessel damage was unknown. This study fills that gap by demonstrating these pathways are activated in diabetes and that blocking them improves blood vessel function. The finding that ER stress triggers these harmful pathways adds a new layer of understanding to how diabetes damages blood vessels.
This research was conducted in mice and laboratory-grown cells, not in humans. The mice were treated for only 5 weeks, so we don’t know if benefits last longer. The study doesn’t tell us whether these compounds would work in people with existing diabetes complications. Additionally, the compounds were given to mice before they developed severe diabetes damage, so it’s unclear if they could reverse existing damage. Finally, the study focused on male mice only, so results might differ in females.
The Bottom Line
Based on this research, reducing ER stress appears to be a promising approach for protecting blood vessels in diabetes (moderate confidence level). The natural compound jatrorrhizine shows particular promise and warrants further investigation. However, these findings are preliminary and should not change current diabetes treatment. People with diabetes should continue taking prescribed medications and following their doctor’s recommendations while researchers conduct human trials.
This research is most relevant to people with type 2 diabetes, especially those at risk for heart disease and blood vessel complications. Researchers studying diabetes complications and pharmaceutical companies developing new treatments should pay close attention. People without diabetes don’t need to change their behavior based on this study.
If these compounds move forward to human testing, it typically takes 5-10 years before new diabetes medications become available to the public. Even then, they would likely be used alongside current treatments, not as replacements.
Frequently Asked Questions
What is endoplasmic reticulum stress and how does it damage blood vessels in diabetes?
ER stress is when a cellular compartment that makes proteins becomes overwhelmed and malfunctions. In diabetes, high blood sugar triggers ER stress, which activates harmful signaling pathways (YAP/TAZ-SMAD1/5) that damage blood vessel cells and reduce their ability to relax properly.
Can jatrorrhizine treat diabetes complications right now?
Not yet. This 2026 study shows jatrorrhizine works in mice and lab cells, but human clinical trials are needed before it can be prescribed. Current diabetes medications remain the standard treatment. Always consult your doctor before trying new supplements.
How long until these new diabetes treatments become available?
If development proceeds smoothly, human trials typically take 5-10 years. Even after approval, new treatments usually complement existing medications rather than replace them. Continued research and regulatory approval are necessary steps.
Does this research apply to type 1 and type 2 diabetes equally?
The study focused on type 2 diabetes mechanisms (high-fat diet model). While the ER stress pathway may be relevant to both types, the specific findings may not apply equally to type 1 diabetes, which has different underlying causes.
What can people with diabetes do now based on this research?
Continue following your doctor’s treatment plan. You can reduce ER stress naturally through adequate sleep (7-9 hours), stress management, regular exercise, and anti-inflammatory eating patterns. Discuss any new approaches with your healthcare provider before trying them.
Want to Apply This Research?
- Users with diabetes could track blood pressure readings weekly and note any changes in energy levels or exercise tolerance, as improved blood vessel function often correlates with these metrics. This creates a personal baseline to discuss with their doctor.
- While waiting for potential new treatments, users can reduce ER stress through proven methods: maintain consistent sleep schedules (7-9 hours), practice stress-reduction techniques like meditation, and follow anti-inflammatory eating patterns. Log these behaviors in the app to identify patterns.
- Set monthly reminders to review blood pressure trends and discuss results with your healthcare provider. Track any changes in exercise capacity or cardiovascular symptoms. Share this data with your doctor to inform treatment decisions.
This article summarizes early-stage research conducted in mice and laboratory cells. These findings have not been tested in humans and should not be used to guide personal medical decisions. People with diabetes should continue taking prescribed medications and following their doctor’s treatment recommendations. Do not start, stop, or change any diabetes medications or supplements without consulting your healthcare provider. This research represents a potential future direction for diabetes treatment, not a current therapeutic option. Always discuss new health information with your doctor before making changes to your care plan.
This research translation is published by Gram Research, the science division of Gram, an AI-powered nutrition tracking app.